CSI Market
Sign In | Register

Immunovant Inc (IMVT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IMVT Annual Cash Flow →
Reviewing cash flow figures over time highlights how Immunovant Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
3 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-153.22
Depreciation & amortization0.09
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation27.31
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Gains Losses On Extinguishments Of Debts-
Write Off Of Deferred Debt Issuance Cost-
Operating Lease Right Of Use Asset Amortization Expense0.07
Increase Decrease In Operating Lease Liability5.71
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.44
Accounts Payable2.60
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense4.95
Other Working Capital-6.76
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.07
Discontinued operations0.00
Net Cash flow from Operating Activities-124.41
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.10
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Sale Of Units-
Repayment Of Convertible Promissory Notes Payable-
Proceeds From Settlement Of Common Shares Subscribed-
Cash Receivaed On Recapitalization Transaction-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents713.97
Purchase Of Property And Equipment In Accounts Payable-
Noncash Or Part Noncash Deferred Initial Public Offering Costs Included In Accrued Expenses-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability0.07
Cash Received On Recapitalization Transaction-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities20.10
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-124.41
Total Cash Flow-104.31
4 historic quarters locked

Sign in to unlock the full Immunovant Inc cash flow history.

Sign In Create Free Account

About Immunovant Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001764013-26-000101

Figures are derived from filed reports and may be restated. Historical data is subject to revision.